Search
Chymopapain
go.drugbank.com/drugs/DB06752ApprovedWithdrawn[L2482]It is an extracellular plant cysteine proteinase similar to papain in specificity.[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982. … Chymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest.
Nivolumab
go.drugbank.com/drugs/DB09035ApprovedInvestigationalNivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). … [L12129] Nivolumab was granted FDA approval on 22 December 2014.[L12129] It is also available in combination with [relatlimab] under the brand name Opdualag.[L41265,L49996,L50001]
Demecarium
go.drugbank.com/drugs/DB00944ApprovedDemecarium is an indirect-acting parasympathomimetic agent that is used to treat glaucoma. It is a cholinesterase inhibitor or an anticholinesterase. … The outflow of the aqueous humor is facilitated, which leads to a reduction in intraocular pressure.
Quinethazone
go.drugbank.com/drugs/DB01325ApprovedQuinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia.
Categories: combinations of sulfonamidesOxacillin
go.drugbank.com/drugs/DB00713ApprovedInvestigationalAn antibiotic similar to [flucloxacillin] used in resistant staphylococci infections.
Categories: combinations of penicillinsInternational brands: Dicloxal OxLight green SF yellowish
go.drugbank.com/drugs/DB11183ApprovedAlthough it has been used as a food colorant, it was discontinued from the market due to low popularity which are possibly due to low durability of the dye and increased tendency of the dye to fade. … Light green SF yellowish is a green triarylmethane dye that is used in the preparation of the staining solution which is widely used as a counterstain.
Synonyms: A F Green No.2, Acid Green AUblituximab
go.drugbank.com/drugs/DB11850ApprovedInvestigational(ADCC), mediated by interactions between an antibody and Fcγ receptors on natural killer cells or macrophages. … [A244195, A244200, A244205] Monoclonal antibodies for B cell depletion rely on their binding affinity and ability to clear bound cells through mechanisms such as antibody-dependent cellular cytotoxicity
Faricimab
go.drugbank.com/drugs/DB15303ApprovedInvestigational[A225985, A225990, A225995] Vascular endothelial growth factor A (VEGF-A) is a well-known mediator of retinal NV, and many currently approved RVD therapies such as [aflibercept] and [ranibizumab] solely … [A225985, A225990, A225995] Faricimab is an IgG<sub>1</sub>-derived bispecific antibody capable of simultaneously binding to and depleting VEGF-A and Ang-2, which has been developed to improve therapeutic
Ceftobiprole medocaril
go.drugbank.com/drugs/DB14733ApprovedCeftobiprole medocaril is a prodrug of [ceftobiprole], a fifth-generation semisynthetic cephalosporin antibacterial. … Union primarily due to data quality issues in pivotal clinical studies.
Abrocitinib
go.drugbank.com/drugs/DB14973ApprovedInvestigationalAbrocitinib is an oral small-molecule inhibitor of Janus kinase 1 (JAK1). … [L39774] The Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signalling pathway plays a central role in the pathogenesis of a variety of autoimmune and inflammatory diseases,